Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher tous les synonymes
Sélectionnez vos espèces d'intérêt
The PIP2-induced orientation of the GRK2-Gbeta1gamma2 complex is therefore most likely caused by specific interactions between PIP2 and the GRK2 PH domain.
Mitochondrial-targeted GRK2 is essential for prodeath signaling occurring after oxidative stress in myocytes and assigning a novel role for this GRK.
Indicate that the anti-proliferative function of elevated GRK2 in hepatocellular carcinoma is associated with delayed cell cycle progression and is GRK2 kinase activity-dependent.
G alpha q/11 interacts with this protein. A novel surface on a regulator of G protein signals a homology domain for binding G alpha subunits (GRK2 kinase}
determined the crystallographic structure of GRK2 in complex with G protein beta1gamma2 subunits.
intramolecular interactions could play a role in regulating G protein-coupled receptor kinase 2 (GRK2).
epithelial Na-channels are maintained in the active state by Grk2; Grk2 phosphorylates the C terminus of the channel beta subunit and renders the channels insensitive to inhibition by Nedd4-2.
Crystallographic and biochemical studies provide evidence that the major domain interfaces of G protein-coupled beta adrenergic receptor kinase 1 (GRK2) remain associated during Gbetagamma binding and activation of GRK2.
Resultrs suggest that activated platelet-derived growth factor receptor-beta (PDGFRbeta) phosphorylates GRK2 tyrosyl residues and thereby activates GRK2, which then serine-phosphorylates and desensitizes the PDGFRbeta.
GRK2-as5 has a role in membrane trafficking of the mu-opioid receptor
atomic structure of GRK2 in complex with Galphaq and Gbetagamma, in which activated Galpha subunit of Gq is fully dissociated from Gbetagamma and dramatically reoriented from its position in the inactive Galphabetagamma heterotrimer [Galphaq, Gbetagamma
G protein-coupled receptor kinase 2 plays a positive role in Smoothened signaling, at least in part, through the promotion of an association between beta-arrestin 2 and Smoothened
M3R activation-induced GRK2 recruitment is Ggamma subtype dependent in which Gbetagamma dimers with low cell membrane-affinity Ggamma9 exhibited a two-fold higher GRK2-recruitment compared to high affinity Ggamma3 expressing cells.
Chronic/pathologic GPCR signaling elicits the interaction of the G-protein Gbetagamma subunit with GPCR kinase 2 (GRK2), targeting the receptor for internalization, scaffolding to pathologic signals, and receptor degradation. Targeting this pathologic Gbetagamma-GRK2 interaction has been suggested as a possible strategy for the treatment of HF.
A novel regulatory role of GRK2 was proposed for the ubiquitination of beta-arrestin in the context of the PKC-mediated heterologous regulation of GPCRs.
eIF3d promotes gallbladder cancer (GBC) progression mainly via eIF3d-GRK2-AKT axis and it may be used as a prognostic factor. The therapeutic targeting of eIF3d-GRK2 axis may be a potential treatment approach for GBC.
KHSV miR-K3 activates the GRK2/CXCR2/AKT axis inducing KSHV-induced angiogenesis and promoting KSHV latency.
Compared to the original peptide, a modified peptide (Ac-EEMEFSEAEANMN-NH2) exhibited markedly higher affinity for GRK2, but very low affinity for GRK5, suggesting that it can be a sensitive and selective peptide for GRK2
Low grk2 expression is associated with lung metastasis in gastric cancer.
Lowering the level of cellular FLNA caused an elevation in RalA activity and resulted in selective interference with the normal intracellular trafficking and signaling of D2R through GRK2.
Results demonstrate that GPR3 signals at the plasma membrane and can be silenced by GRK2/beta-arrestin overexpression. These results also strongly implicate the serine and/or threonine residues in the third intracellular loop in the regulation of GPR3 activity.
GRK2 is negatively related to IGF1R and IGF1R, but not GRK2, was associated with the tumour-node-metastasis stage and overall and disease-free survival in hepatocellular carcinoma.
The tyrosine-phosphorylated GRK2 mediates this inhibition by acting on the second intracellular loop of D3R.
GRK2 is overexpressed in pancreatic cancer, and might serve as a potential indicator of unfavorable prognosis.
Data, including data from studies in heterozygous knockout mice, suggest that GRK2 is involved in TNFalpha-induced wound healing in epithelial cells of the colon; GRK2 appears to inhibit TNFalpha-induced apoptosis; GRK2 inhibits TNFalpha-induced ERK activation by inhibiting generation of reactive oxygen species. Homozygous knockout of GRK2 is embryonically lethal in mice.
The dominant model (CC vs. CT+TT) of rs1894111 polymorphism in the ADRBK1 gene might be associated with low-renin hypertension in Han Chinese.
Our data suggest that GRK2 acts as an important onco-modulator by strengthening the functionality of key players in breast tumorigenesis such as HDAC6 and Pin1.
GRK2 may inhibit IGF1-induced human hepatocellular carcinoma cell growth and migration through downregulation of EGR1.
It is a critical factor in diabetic endothelial dysfunction and plays a role in many physiological functions including regulation of G-protein-coupled receptors (GPCRs). (review)
Suggest a common regulatory pattern for the beta(2)-AR/GRK2 which is independent of cellular type or pathology.
Suggest role for GRK2 in the regulating cardiac hypertrophy.
the dual-specific GRK2 and ERK cascade inhibitor, RKIP (Raf kinase inhibitor protein), triggered dysfunctional cardiomyocyte energetics and the expression of heart failure-promoting Pparg-regulated genes.
The product of this gene phosphorylates the beta-2-adrenergic receptor and appears to mediate agonist-specific desensitization observed at high agonist concentrations. This protein is an ubiquitous cytosolic enzyme that specifically phosphorylates the activated form of the beta-adrenergic and related G-protein-coupled receptors. Abnormal coupling of beta-adrenergic receptor to G protein is involved in the pathogenesis of the failing heart.
beta-adrenergic receptor kinase 1
, adrenergic, beta, receptor kinase 1
, G-protein-coupled receptor kinase 2
, beta ARK
, beta ARK1
, beta-AR kinase-1
, beta-adrenergic receptor kinase-1
, G-protein coupled receptor kinase 2
, adrenergic receptor kinase, beta 1
, beta-adrenergic receptor kinase 1 beta ARK1